A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women

OBJECTIVES: The exploratory objectives of this study were to evaluate the usability and acceptability and to conduct a preliminary evaluation of the efficacy of DARE-HRT1. DARE-HRT1 is an intravaginal ring (IVR) that releases 17β2-estradiol (E(2)) with progesterone (P(4)) over 28 days. It is the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Thurman, Andrea, Hull, M. Louise, Stuckey, Bronwyn, Hatheway, Jessica, Zack, Nadene, Mauck, Christine, Friend, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487358/
https://www.ncbi.nlm.nih.gov/pubmed/37625088
http://dx.doi.org/10.1097/GME.0000000000002230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10487358/
https://www.ncbi.nlm.nih.gov/pubmed/37625088
http://dx.doi.org/10.1097/GME.0000000000002230

Ejemplares similares